Categories: Reuters

EU places China’s Zhejiang Huahai under increased supervision

(Reuters) – European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

EU authorities will now supervise the manufacture of other active substances produced by Zhejiang Huahai more closely, the regulator said on Monday.

European authorities said late last month they had found that Huahai did not comply with good manufacturing practices and that the company’s factory in Linhai, China, was no longer authorized to produce valsartan.

The bulk manufacturer of the high blood pressure drug recalled the product in the United States in July after an impurity linked to cancer was detected.

European and North American regulators last month found a second toxin in Valsartan that may cause cancer in humans.

The review was extended to other ‘sartan’ medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

EMA said on Monday low levels of a carcinogen have now also been found in irbesartan made by Aurobindo Pharma, with the supply in the EU of medicines containing irbesartan in EU being suspended.

National authorities in the EU are currently considering whether to recall medicines containing Aurobindo Pharma’s irbesartan from pharmacies as a precaution, the regulator said

(Reporting by Ankur Banerjee in Bengaluru; Editing by Sai Sachin Ravikumar and Shailesh Kuber)


Recent Posts

  • Reuters

Amateur rock climbers often lack skills to save themselves

By Carolyn Crist (Reuters Health) - - Most hobbyist rock climbers lack the basic rescue skills needed to save themselves…

21 mins ago
  • Doctor's Voice

A Lesson a Patient Taught Me About Dying

The following was originally posted to Dr. Linda. Being the intern on the team, I knew the scut work belonged…

1 hour ago
  • Reuters

U.S. top court rejects Helsinn over anti-nausea drug patent in win for Teva

By Andrew Chung WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday refused to revive Swiss drug company Helsinn Healthcare…

2 hours ago
  • Reuters

U.S. insulin costs per patient nearly doubled from 2012 to 2016: study

By Robin Respaut and Chad Terhune (Reuters) - The cost of insulin for treating type 1 diabetes in the United…

6 hours ago
  • Reuters

Study in WHO journal likens palm oil lobbying to tobacco and alcohol industries

(The original headline of this Jan. 8 story referred to a "WHO study". the study was published in the WHO's…

6 hours ago
  • Reuters

Many migraine sufferers wary of alcohol as a headache trigger

By Carolyn Crist (Reuters Health) - - Many migraine sufferers avoid alcohol, saying it can trigger the severe headaches, a…

18 hours ago